Although release of ICD modulators such as HMGB1 could lead to the influx of myeloid cells because of their chemoattractive properties (Ahmed and Tait, 2020), the modest effects observed here suggest that this is unlikely to be a major factor contributing to the therapeutic efficacy of low-dose CPM in neuroblastoma models. This evidence concerns the gene HMGB1 and neuroblastoma.